Assetmark Inc. Acquires 152,249 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Assetmark Inc. boosted its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 56.9% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 419,957 shares of the biotechnology company's stock after purchasing an additional 152,249 shares during the quarter. Assetmark Inc. owned about 0.94% of United Therapeutics worth $150,492,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. ClariVest Asset Management LLC grew its holdings in shares of United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company's stock valued at $25,000 after buying an additional 42 shares during the last quarter. USA Financial Formulas purchased a new stake in shares of United Therapeutics during the third quarter valued at approximately $33,000. V Square Quantitative Management LLC purchased a new stake in shares of United Therapeutics during the second quarter valued at approximately $30,000. Innealta Capital LLC purchased a new stake in United Therapeutics in the second quarter worth approximately $33,000. Finally, Capital Performance Advisors LLP purchased a new stake in United Therapeutics in the third quarter worth approximately $82,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

Insiders Place Their Bets

In other United Therapeutics news, Director Christopher Causey sold 510 shares of the business's stock in a transaction on Friday, November 1st. The shares were sold at an average price of $376.63, for a total value of $192,081.30. Following the sale, the director now owns 3,675 shares in the company, valued at $1,384,115.25. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the business's stock in a transaction on Monday, August 19th. The shares were sold at an average price of $344.18, for a total value of $1,239,048.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at $44,743.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christopher Causey sold 510 shares of the business's stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $376.63, for a total transaction of $192,081.30. Following the completion of the sale, the director now owns 3,675 shares in the company, valued at approximately $1,384,115.25. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 96,422 shares of company stock worth $35,251,428 in the last 90 days. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Price Performance

Shares of UTHR stock traded up $7.43 on Friday, hitting $410.00. 498,743 shares of the stock traded hands, compared to its average volume of 464,869. The firm has a market cap of $18.30 billion, a price-to-earnings ratio of 18.01, a PEG ratio of 1.16 and a beta of 0.56. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82. The firm has a 50 day simple moving average of $359.20 and a two-hundred day simple moving average of $322.16.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating the consensus estimate of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company's revenue was up 22.9% on a year-over-year basis. During the same period last year, the firm earned $5.38 EPS. Sell-side analysts forecast that United Therapeutics Co. will post 25.1 EPS for the current year.

Wall Street Analysts Forecast Growth

UTHR has been the topic of several research reports. HC Wainwright raised their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. LADENBURG THALM/SH SH raised their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. Wells Fargo & Company raised their target price on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an "overweight" rating in a report on Tuesday, August 20th. The Goldman Sachs Group raised their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a report on Friday, November 1st. Finally, Jefferies Financial Group raised their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a "buy" rating in a report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, United Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $370.86.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.